(Journal of Vascular Surgery[TA])
20,753 results
  • Long-term clinical effectiveness of endovenous interventions for pelvic venous disorders. [Journal Article]
    J Vasc Surg Venous Lymphat Disord. 2026 Aug 05; :102597. [Online ahead of print]Ma N, Lakhanpal G, … Pappas PJJV
  • CONCLUSIONS: Women with PeVD often present with concomitant pelvic and lower extremity venous symptoms. Regardless of symptomatology or treatment modality, patients report improved and sustained symptom relief up to 36 months. Patients receiving OVE + ST demonstrated maximal pain reduction at one month with sustained relief up to 36 months whereas OVE or ST patients alone required 3 months for maximal and sustained pain reduction. These data suggest that combined therapies provide faster pain relief in patients with ovarian vein reflux and iliac vein stenoses. If a staged approach with OVE followed by stenting is employed, ST should be considered at 3 months as no further improvement at six months was observed.
  • Evaluation of venous anatomy after treatment with an intraluminal tissue debulking system in a porcine model. [Journal Article]
    J Vasc Surg Venous Lymphat Disord. 2026 Aug 05; :102595. [Online ahead of print]Marston W, Dooley E, Chinubhai AJV
  • CONCLUSIONS: In an in-vivo model of stented and native iliac veins, a novel venous tissue debulking system was able to engage intraluminal material without serious injury. Vein wall trauma was comparable to a commonly used mechanical thrombectomy device, with no transmural lacerations or device-related hemorrhage. These findings support continued development toward initial clinical trials in patients with venous obstruction.
  • Optimising the management of venous disease: Expert consensus from a multinational panel of phlebology specialists. [Review]
    J Vasc Surg Venous Lymphat Disord. 2026 Aug 04; :102593. [Online ahead of print]Matei SC, Nikolov N, … Ilijevski NJV
  • Chronic venous disease (CVD) and varicose veins (VV) are highly prevalent yet remain inconsistently managed despite existing guidelines, with variability in treatment selection, patient stratification, and use of conservative therapies. This multinational initiative sought to establish expert consensus on key clinical questions in venous disease management. A Delphi-like process involved 38 phleb…
  • A Systematic Review on Imaging and Diagnostic Modalities for the Detection, Evaluation, and Surgical Planning of Upper and Lower Extremity Lymphedema. [Review]
    J Vasc Surg Venous Lymphat Disord. 2026 Aug 03; :102592. [Online ahead of print]Lewis SK, Pina C, … Oropallo AJV
  • CONCLUSIONS: This systematic review identified important differences in the evidence supporting imaging and diagnostic modalities across the four clinical domains evaluated. For diagnosis and subclinical detection, BIS-triggered prospective surveillance for upper extremity lymphedema is supported by RCT evidence demonstrating significant reduction in chronic BCRL progression. However, comparable trial data for the lower extremity remains absent. For anatomical assessment, region-specific ICG classification systems (SCaT and Shinaoka) address the unique drainage patterns of the lower extremity, while MRL provides comprehensive deep and superficial system visualization across both regions. For surgical planning, the combined use of NIRF-L and MRL offers complementary information to guide microsurgical interventions.
  • Dual antiplatelet therapy is not associated with target vessel occlusion or bleeding complications following fenestrated and branched aortic repair. [Journal Article]
    J Vasc Surg. 2026 Aug 03. [Online ahead of print]Murphy BE, Anderson G, … Zettervall SLJV
  • CONCLUSIONS: DAPT was not associated with a significant reduction in TV occlusion following F/BEVAR. However, complete cessation of antithrombotic medications increases risk for TV occlusion, highlighting the critical importance of continued adherence to antiplatelet therapy. Bleeding complications are more common with long-term AC+SAPT, but not DAPT. Randomized control trials are needed to further delineate optimal antithrombotic medication regimens given the high-risk comorbidity profile of patients treated and associated impact of TV occlusion and bleeding events on patient outcomes.
  • Safety of Iliac Vein Stenting in the Office-Based Laboratory: Experience with 4,312 Nonthrombotic Iliac Vein Lesions. [Journal Article]
    J Vasc Surg Venous Lymphat Disord. 2026 Aug 01; :102594. [Online ahead of print]Srivastava S, Ascher E, Hingorani AJV
  • CONCLUSIONS: Iliac vein stenting for symptomatic nonthrombotic iliac vein lesions (NIVL) is a safe and effective procedure with a low incidence of early thrombosis. Age, laterality, and CEAP clinical class were not significantly associated with 30-day thrombosis outcomes. This study supports the use of iliac vein stenting in patients across a broad spectrum of CVI severity, demonstrating its effectiveness in an outpatient-based laboratory (OBL) setting.
  • Systematic Review of Pediatric Abdominal Aortic Aneurysms. [Review]
    J Vasc Surg. 2026 Jul 29. [Online ahead of print]Ballan D, Aljobeh A, … Tassiopoulos AJV
  • CONCLUSIONS: Pediatric AAAs represent a heterogeneous and clinically significant entity distinct from adult disease. Early recognition in high-risk populations and timely surgical intervention are critical. Given the absence of pediatric-specific guidelines, multicenter collaboration and long-term surveillance data are needed to inform evidence-based management strategies.
  • Adjunctive Citrus Flavonoids After Endovenous Microwave Ablation for Great Saphenous Vein Varicosis: A Retrospective Cohort Study. [Journal Article]
    J Vasc Surg Venous Lymphat Disord. 2026 Jul 28; :102586. [Online ahead of print]Rui Y, Chen WJV
  • CONCLUSIONS: In this retrospective cohort, adjunctive citrus flavonoids after EMA were associated with better early symptom scores, venous haemodynamic indices, and endothelial biomarker profiles without a detected increase in recorded adverse events. Because the study was observational and used a non-standard MPFF dose, these findings should be interpreted as associations rather than evidence of causality, proof of safety, or support for the 2000 mg/day regimen. Prospective randomised trials using approved dosing are needed for confirmation.